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A B S T R A C T
The human gut microbiome can now be characterized in unprecedented detail by an
approach based on high-throughput sequencing of total stool DNA, that we name
quantitative metagenomics. Central to the approach is a catalog that lists all the genes of
intestinal microbes that are known – 9.9 millions, identiﬁed by the analysis of 1267 stool
samples. Beyond the gene list, genetic units that carry them begun to be known; many of
these correspond to bacterial species that were never isolated and cultured yet.
Quantitative metagenomics allows developing powerful algorithms to diagnose a disease,
monitor patients and identify individuals at risk to progress towards a disease. This lays
ground for developing new approaches to better restore and even preserve the health by
modulation of the altered microbiome, which contributes to promote or aggravate a
disease.
 2016 Acade´mie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
R E´ S U M E´
Le microbiote intestinal humain peut maintenant eˆtre caracte´rise´ en de´tail par une
approche base´e sur le se´quenc¸age a` haut de´bit de l’ADN total des selles, que nous appelons
me´tage´nomique quantitative. Le cœur de l’approche est un catalogue qui re´pertorie tous
les ge`nes des microbes intestinaux qui sont connus – 9,9 millions, identiﬁe´s par l’analyse
de 1267 e´chantillons de selles. Au-dela` de la liste des ge`nes, les unite´s ge´ne´tiques qui les
portent commencent a` eˆtre connues ; beaucoup d’entre elles correspondent a` des espe`ces
bacte´riennes qui n’ont jamais e´te´ isole´es et encore moins cultive´es. La me´tage´nomique
quantitative permet de de´velopper des algorithmes puissants pour diagnostiquer une
maladie, de surveiller les patients, ainsi que d’identiﬁer les personnes qui pre´sentent un
risque de de´velopper une maladie. Cela jette les bases du de´veloppement de nouvelles
approches pour mieux restaurer et meˆme pre´server la sante´ par modulation d’un
microbiote alte´re´ qui contribue a` favoriser ou a` aggraver une maladie.
 2016 Acade´mie des sciences. Publie´ par Elsevier Masson SAS. Cet article est publie´ en
Open Access sous licence CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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The human gut microbiome can be thought of as our
neglected organ [1]. It is comprised of more microbial cells
than the remainder of our body, can weigh two kilograms,
more than most other organs, and has a considerable
metabolic activity. The microbial organ is not indispen-
sible, as germ-free animals are viable. However, their
development is impacted as their gastrointestinal tract,
immune system and even brain are not fully mature, and
we do not know whether their life outside of the strictly
sterile conditions where they are maintained would be
possible. The microbial communities that compose the
neglected organ are altered in numerous diseases, in
particular the chronic ones, which are constantly increas-
ing in the industrialized societies [2]. This raises the
possibility that the organ may play a role in these diseases.
But why has it remained neglected, while it clearly should
have been investigated? A simple answer is that there were
no appropriate tools to study it. A traditional way to
characterize microbial communities is to enumerate the
species that they contain by culturing them in appropriate
media, but for most of the microbial species from our gut
we still do not have such media and do not know how to
grow them reliably. The situation has changed by the
advent of molecular methods precise enough to detect
most of the species and determine their abundance.
2. Quantitative metagenomics for microbiome
assessment
The method has been developed in the European
MetaHIT consortium (http://www.metahit.eu/), opera-
tional between 2008 and 2012, and relies on the advent
of new generation sequencing (NGS) techniques, capable
of generating millions of sequencing reads in parallel and
the numerical tools capable of handling Big Data (Fig. 1). A
catalog listing the genes of intestinal microbes is central to
the approach. It is used to determine the presence and the
abundance of each gene in any sample under study, that is,
the gene proﬁle of any individual at a given point in time. A
view of the microbiome of unprecedented precision is
thus obtained. Comparisons of microbiomes (gene pro-
ﬁles) of different individuals, say patients and healthy
controls, reveal the genes and species that distinguish
them, by their presence or their abundance. The contrast-
ing genes and species can be used, in turn, to develop
powerful diagnostic and even prognostic algorithms of
clinical relevance.
The ﬁrst gene catalog was established in 2010, ten
years after the sequencing of the human genome, by the
analysis of 124 individuals of European origin [3]. It
contains 3.3 million genes (> 99% bacterial, remainder of
viral and eukaryote origin), 150 times more than our
own genome, and was dubbed our other genome. An
updated version of the catalog was released four years
later. It contains 9.9 million genes, found by analyzing
ten times more individuals from three continents
(Europe, Asia and North America), and the sequenced
reference genomes of cultured gut species [4]. Notably,
the number of genes found in at least 5% of analyzed
individuals increase little with each additional sample,
whereas that of genes harbored by only a few individuals
continue to increase, without sign of saturation. The
former may approximate ‘‘core’’ components of the
microbiome, whereas the latter can be viewed as
‘‘individualized’’ parts, corresponding likely, on the
one hand, to transient rather than to resident gut
Fig. 1. Quantitative metagenomics for the characterization of the human gut microbiome. Total DNA is extracted from a stool sample, sequenced to
generate millions of reads; the reads are mapped to a reference catalog that lists all the known gut microbial genes, and a gene count table is generated foreach sample. The counts are converted into gene proﬁles, the proﬁles are related to bioclinical data, and the models of clinical relevance are generated.
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S.D. Ehrlich / C. R. Biologies 339 (2016) 319–323 321cies, introduced from the environment (e.g., microbes
d in food fermentation) and, on the other hand, to
in differences between the resident species. The core
t, which starts to be described in a rather compre-
sive way, is most useful to address health-related
stions of large populations.
Of course, genes are encoded on various genetic units,
h as bacterial chromosomes or sub-chromosomal
ments (phages, plasmids, CRISPR elements, virulence
nds, etc.). A method to cluster genes carried on the
e genetic units was developed in the MetaHIT
sortium [5]. It is based on two simple facts. First,
 genes carried on the same genetic unit must have the
e abundance. Second, the abundance of different
etic units varies greatly between individuals (10- to
0-fold, as assessed using known reference genomes
sent in more than 90% of the individuals [3]).
refore, the genes that co-vary in abundance when
erent individuals are analyzed are encoded by the
e genetic units.
Two types of clusters were found, differing by the
ber of genes. The ﬁrst, containing more than
 genes, correspond to bacterial species and are
oted MGS for MetaGenomic Species, the second
tered on 50 genes and denoted MGU (for MetaGe-
ic Units) to smaller genetic elements. Some
 MGS were revealed, and 85% of them were never
lated and had no closely related reference genomes,
about 240 high-quality genomes were assembled
 short sequencing reads. Almost 10-fold more MGU
re found; many of those were observed only in the
sence of a given MGS, as expected, for instance, for a
ge, which needs a speciﬁc host. The ensemble
resents the most detailed species and sub-species
el description of the human gut microbiome.
icrobiome-based diagnostics
The method, quantitative metagenomics, and the
ailed description of the microbiome, based on MGS
 MGU, largely set the scene to investigate the
position of the gut microbial communities in the
ase. As an example of the power of the approach, likely
st advanced today, we can cite that of liver cirrhosis [6].
A cohort of 123 patients and 114 healthy controls was
died and a massive gut microbial dysbiosis was
ected in the former. First, patients have lost a large
portion of their microbial richness, some 25%, as is
n observed in chronic diseases (Crohn’s disease
robiome as an early harbinger [7]). Some 28 MGS,
ich were rare in healthy individuals, were overabun-
t in patients – collectively, they constituted a large
tion of the microbiome, up to 40%! These invading
cies displaced another 38 that are common and
ndant in the healthy individuals. Interestingly, the
aders were mostly the species that are normally found
he mouth, but also food-borne pathogens. How could
y ever become established in the gut? Likely, because
 bile salt production is deﬁcient in liver cirrhosis. Bile is
ic for most microorganisms but the normal gut
idents thrive in its presence – it can be viewed as a
barrier that protects the gut ecosystem from foreign
microbes.
The massive dysbiosis found in liver cirrhosis allows
constructing powerful diagnostic algorithms. Using only
seven most informative MGS, liver cirrhosis can be
detected by stool analysis, in a fully non-invasive way,
with an accuracy of about 95%. Microbiome-based
diagnosis has a potential to replace the current diagnostic
golden standard, the invasive liver biopsy.
4. Microbiome-based patient monitoring
What could be the physio-pathological consequences of
the massive invasion of the gut by oral bacteria?
Quantitative metagenomics detects every gene of a catalog
and allows carrying out metabolic reconstruction of the
dysbiotic microbiome. It has revealed that the microbiome
found in liver cirrhosis could overproduce ammoniac, a
neurotransmitter gamma-aminobutyric acid (GABA) and
impact manganese metabolism. These three factors are
associated with a serious complication of liver cirrhosis,
the hepatic encephalopathy; possibly, the altered micro-
biome aggravates the disease. Indeed, comparing the
patients with the lowest load of the invading species with
those with the highest load has revealed that the latter
have signiﬁcantly worse clinical scores (Model for End
stage Liver Disease [MELD] and Child–Turcotte–Pugh
[CTP]); their disease is more serious [6]. This example
illustrates how microbiome analysis can be used to
monitor the progression of the disease.
5. Microbiome-based risk detection
The detection of the risk to develop a chronic disease is
a ﬁrst step towards prevention, which can barely be
achieved today. A study of a Danish cohort of some
292 individuals has revealed that almost one in four has
lost a substantial proportion of his/her gut microbial
richness, on average 40% [8]. This loss of richness was
accompanied with a substantial alteration of the composi-
tion of gut microbial communities. Microbe-poor individ-
uals had higher levels of pro-inﬂammatory species and
lower levels of anti-inﬂammatory species. Consistently,
the analysis of the genetic potential of the former indicated
a higher propensity to synthesize the pro-inﬂammatory
endotoxin LPS. In parallel, the capacity to synthesize
butyrate, a substance necessary for the enterocytes that
our own body cannot make, appeared to be signiﬁcantly
decreased. Most interestingly, the microbe-poor individu-
als displayed higher adiposity, insulin resistance, dyslipi-
demia, and inﬂammation, which, taken together, are signs
of predisposition for type-2 diabetes, hepatic and cardio-
vascular complications and some types of cancer. Not only
were these individuals predisposed to develop serious
chronic diseases, but they had also, when obese, put on
signiﬁcantly more weight over the past 9 years than their
microbe-rich counterparts, thus aggravating their health
status.
A similar analysis of a French cohort of 49 individuals
conﬁrmed these observations: microbe-poor and rich
individuals were found, with comparable phenotypes to
S.D. Ehrlich / C. R. Biologies 339 (2016) 319–323322those revealed in the Danish study [9]. The individuals at
risk can be identiﬁed with high accuracy, close to 95%,
using an algorithm based on only six informative MGS.
6. Risk alleviation by microbiome remodeling
Ideally, risk detection should be accompanied by risk
alleviation. Can the lost microbiome richness be recov-
ered? Nutritional data revealed an association of the
richness with the consumption of fruit and vegetables,
which could be mediated by the high ﬁber content of these
foods [9]. An intervention study in the French cohort, with
calorie-restricted diet having high ﬁber and protein but
low fat content led to an improvement of the bioclinical
parameters, as expected, but also to an increase of the
richness of microbe-poor individuals, by 30% [9]. These
encouraging results prompt further exploration of the
possibilities to prevent chronic disease by microbiome
remodeling.
7. Cause or consequence – an irrelevant question?
A question often asked is whether the gut microbiome
alterations are a cause or a consequence of the disease
[10]. However, a better question may be whether the altered
microbiome contributes to the disease. The case can be well
illustrated, once again, by liver cirrhosis. The three main
causes of cirrhosis are virus infection, alcohol consumption,
and obesity, which all lead to liver dysfunction; it is unlikely
that microbiome alterations play a major role in triggering
this disease. The resulting liver dysfunction likely promotes
microbiome alteration; we hypothesize that bile production
deﬁcit renders the gut permissive to microbes normally
foreign to this ecosystem. That would be a clear case of
microbiome alteration as a consequence of the disease.
However, the altered microbiome, in turn, may aggravate
the disease, as it has the potential to overproduce toxic
substances such as ammoniac and GABA, and to impact
manganese metabolism; all three are thought to play a role
in hepatic encephalopathy [11]. Interestingly, treatments
that are currently used, laxatives, antibiotics, and enemas,
actually target the microbiome. The beneﬁts are only
temporary, likely because they do not prevent the reconsti-
tution of the harmful microbiome; a more permanent
modulation could be sought as a novel way to treat this
disease. We suggest that this may well be the case in many
other diseases, and, whatever the trajectory that leads to the
alteration of the neglected microbial organ of our body, it
needs to be treated to the best of our abilities, in order to
improve the patients’ health.
In a similar vein, inﬂammation is a facet of many
chronic diseases and might promote their advent, but is
not necessarily their immediate cause. The loss of gut
microbiome richness found in a high proportion of
otherwise healthy individuals corresponds to an alter-
ation of the neglected organ, which promotes inﬂamma-
tion, likely due to endotoxin production [8]. The treatment
of the altered neglected organ, aiming at recovering
its richness, might reduce the risk of developing a
8. Ways forward
A panel of ways to modulate the microbiome can be
envisaged and has indeed begun to be explored. It extends
from nutritional interventions [9] all the way to
organ transplantation [12], and includes treatments with
molecules (promoters of beneﬁcial components of the
community or inhibitors of the potentially harmful ones,
e.g., prebiotics and narrow range antibiotics, respectively)
and living organisms (probiotics, artiﬁcial communities).
Translating these novel ways into practices of societal impact
will require industry carry-over – the ﬁeld has reached the
level of maturity where this is already happening, as
witnessed by interest of early start-ups such as Enterome
(http://www.enterome.fr/), worldwide actors such as
Danone or Johnson and Johnson as well as investment funds,
such as Seventure (http://www.latribune.fr/entreprises-
ﬁnance/industrie/chimie-pharmacie/le-microbe-nouvelle-
star-des-labos-554755.html, for a recent public media view).
Hopefully, public policies concerned with health and disease
will begin to reﬂect this ongoing rupture.
9. Conclusion
Knowledge of the human microbiome will alter our views
on health and disease and likely lead to novel ways to
preserve health and better treat the disease. Mechanistic
insights into the interactions between the microbial organ
and the remainder of our body should be vigorously pursued,
as they will lead to a better understanding of our biology and
lay solid ground for interventions aiming at achieving these
goals. But it is safe to say that these insights will take long to
be acquired. In the meantime, without wasting time, even
the current, albeit limited, knowledge of the microbiome
should encourage us to strive to restore or preserve health by
modulating unhealthy or toxic microbiomes.
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